Open access · CC-BY
via OpenAlex
Genome-wide transcriptomics identifies an early preclinical signature of prion infection
Silvia Sorce, Mario Nuvolone, Giancarlo Russo, Andra Chincisan, Daniel Heinzer, Merve Avar, Manuela Pfammatter, Petra Schwarz, Mirzet Delic, Micha Müller, Simone Hornemann, Despina Sanoudou, Claudia Scheckel, Adriano Aguzzi
PLoS Pathogens · 2020 · ▲ 59 citations
Abstract
The clinical course of prion diseases is accurately predictable despite long latency periods, suggesting that prion pathogenesis is driven by precisely timed molecular events.We constructed a searchable genome-wide atlas of mRNA abundance and splicing alterations during the course of disease in prion-inoculated mice.Prion infection induced PrP-dependent transient changes in mRNA abundance and processing already at eight weeks post inoculation, well ahead of any neuropathological and clinical signs.In contrast, microglia-enriched genes displayed an increase simultaneous with the appearance of clinical signs, whereas neuronal-enriched transcripts remained unchanged until the very terminal stage of disease.This suggests that glial pathophysiology, rather than neuronal demise, could be the final driver of disease.The administration of young plasma attenuated the occurrence of early mRNA abundance alterations and delayed signs in the terminal phase of the disease.The early onset of prion-induced molecular changes might thus point to novel biomarkers and potential interventional targets. Author summaryPrion diseases are brain disorders caused by infectious proteins called prions.These diseases feature a long asymptomatic incubation phase which can last several years, followed by a phase of rapidly progressing mental deterioration that can lead to death within just few months.The mechanisms underlying the long incubation phase are elusive, impeding early diagnosis and limiting potential therapeutic interventions.In experiments, prioninfected mice develop the disease following a timeline similar to that of human prion diseases.Here we have studied gene expression at different time points during the development of disease in mice.Our results indicate that robust molecular changes can be
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1371/journal.ppat.1008653
- Canonical
- link ↗
- Fetched
- 2026-11-16 MST
Cite this
APA
Sorce, S., Nuvolone, M., Russo, G., Chincisan, A., Heinzer, D., Avar, M., Pfammatter, M., Schwarz, P., Delic, M., Müller, M., Hornemann, S., Sanoudou, D., Scheckel, C., & Aguzzi, A. (2020). Genome-wide transcriptomics identifies an early preclinical signature of prion infection. <em>PLoS Pathogens</em>. https://doi.org/10.1371/journal.ppat.1008653
Vancouver
Sorce S, Nuvolone M, Russo G, Chincisan A, Heinzer D, Avar M, et al. Genome-wide transcriptomics identifies an early preclinical signature of prion infection. PLoS Pathogens. 2020. doi:10.1371/journal.ppat.1008653.
BibTeX
@article{silvia2020Genome,
title = {Genome-wide transcriptomics identifies an early preclinical signature of prion infection},
author = {Silvia Sorce and Mario Nuvolone and Giancarlo Russo and Andra Chincisan and Daniel Heinzer and Merve Avar and Manuela Pfammatter and Petra Schwarz and Mirzet Delic and Micha Müller and Simone Hornemann and Despina Sanoudou and Claudia Scheckel and Adriano Aguzzi},
journal = {PLoS Pathogens},
year = {2020},
doi = {10.1371/journal.ppat.1008653},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
University of California, San Diego 2011
Open access · US-GOV
Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab (COMPASS)
PINER Pastor Manfredi Winery 2022
Open access · US-GOV
Biological Effects in Consumers of Resveratrol-enriched Wine
Minicircle 2022
Open access · US-GOV
A Phase I, Open Label, Single Dose Study to Evaluate the Safety and Efficacy of an Injectable Follistatin Plasmid Gene Therapy in Healthy Subjects
Molecular Oncology 2007
Open access · OA
Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis
PharmaBio Corporation 2024
Open access · US-GOV
Phase I/IIa Clinical Study of PAL-222 Targeting Patients With Neovascular Age-related Macular Degeneration (AMD) That Shows no Response to Existing Therapy
Sound Wave Innovation CO., LTD. 2023
Open access · US-GOV